

Freedom of Information Request

- I am researching the use of biologic products. Could you please provide answers to the following three questions:

Q1. How many patients have been treated (for any disease) in the last three months with:

- **Benralizumab - 0**
- **Omalizumab - 11**
- **Reslizumab – 0**
- **Mepolizumab - 0**

Q2. How many patients have been treated in the last three months, for asthma ONLY, with:

- **Dupilumab - 0**
- **Upadacitinib - 0**

Q3. How many patients have been treated (with any medication) for severe asthma in the last three months? Of these patients, how many were children?

Notes:

"Severe asthma" cases are taken as those requiring a hospital admission, for which there was a primary diagnosis of Asthma.

All of these patients would have been treated with some form of medication for severe asthma on admission.

To qualify as Asthma, an ICD-10 primary diagnosis codes of J46.X (Status Asthmaticus) or any J45 code (Asthma) must have been coded for the spell.

Children are classed as those under 14 years at their date of discharge, with adults being 14 years and older at that time.

Table A, below, counts discharges. Day Cases admissions are excluded from this.

One adult patient spell had a primary diagnosis of J45.0 (Predominantly Allergic Asthma), whilst the rest had J45.9 (Asthma, unspecified). No cases with the acute severe asthma code, J46.X, were found in these months.

All the spells below were non-elective cases.

Three adult patients each had two spells during this quarter, so there were 28 unique patients.

Table A: Counts of discharges by Age Band and Month of Discharge (October 2020 to December 2020).

Discharges (Hospital Spells)	2020/10	2020/11	2020/12	
	October	November	December	Totals:
Adult (>= 14y)	13	9	1	23
Child (under 14y)	1	3	4	8
Totals:	14	12	5	31